B. Riley Forecasts Immunic’s FY2024 Earnings (NASDAQ:IMUX)

Immunic, Inc. (NASDAQ:IMUX) – Equities research analysts at B. Riley dropped their FY2024 earnings estimates for Immunic in a report issued on Tuesday, November 26th. B. Riley analyst W. Wood now anticipates that the company will post earnings of ($0.97) per share for the year, down from their previous estimate of ($0.93). B. Riley has a “Buy” rating and a $6.00 price objective on the stock. The consensus estimate for Immunic’s current full-year earnings is ($0.93) per share. B. Riley also issued estimates for Immunic’s Q4 2024 earnings at ($0.26) EPS, Q1 2025 earnings at ($0.29) EPS, Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.35) EPS and FY2025 earnings at ($0.80) EPS.

A number of other equities research analysts have also recently commented on IMUX. Leerink Partners reissued an “outperform” rating and issued a $5.00 price objective on shares of Immunic in a research note on Monday, September 9th. Leerink Partnrs raised shares of Immunic to a “strong-buy” rating in a research report on Monday, September 9th. StockNews.com lowered shares of Immunic from a “hold” rating to a “sell” rating in a research note on Monday, November 11th. HC Wainwright initiated coverage on shares of Immunic in a research note on Monday. They issued a “buy” rating and a $10.00 price objective on the stock. Finally, EF Hutton Acquisition Co. I raised shares of Immunic to a “strong-buy” rating in a research report on Monday, September 16th. One analyst has rated the stock with a sell rating, five have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $11.80.

Immunic Price Performance

Shares of IMUX opened at $1.20 on Thursday. Immunic has a one year low of $0.97 and a one year high of $2.11. The company has a market cap of $108.09 million, a PE ratio of -0.98 and a beta of 1.88. The stock has a 50-day moving average of $1.37 and a 200-day moving average of $1.34.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Janus Henderson Group PLC purchased a new stake in shares of Immunic during the 1st quarter valued at $9,266,000. Vanguard Group Inc. grew its position in Immunic by 100.7% during the first quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company’s stock valued at $4,480,000 after buying an additional 1,703,047 shares during the period. State Street Corp increased its holdings in Immunic by 7.5% during the third quarter. State Street Corp now owns 167,145 shares of the company’s stock worth $276,000 after buying an additional 11,642 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its position in Immunic by 70.8% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock worth $169,000 after acquiring an additional 42,383 shares during the period. Finally, Jane Street Group LLC boosted its stake in Immunic by 121.4% in the third quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock valued at $116,000 after acquiring an additional 38,553 shares during the last quarter. Hedge funds and other institutional investors own 51.82% of the company’s stock.

Insider Activity

In other Immunic news, Director Richard Alan Rudick bought 87,300 shares of Immunic stock in a transaction dated Tuesday, November 12th. The stock was bought at an average cost of $1.15 per share, with a total value of $100,395.00. Following the completion of the acquisition, the director now directly owns 87,300 shares in the company, valued at approximately $100,395. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 3.00% of the stock is currently owned by corporate insiders.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.